文献速递皮肤肿瘤

黑色素瘤DNA甲基化组分析:LY75甲基化独立预测不良临床结局

Comprehensive Analysis of the Melanoma DNA Methylome Identifies LY75 Methylation as an Independent Marker Predicting Poor Clinical Outcome.
PubMed 文献 · J Invest Dermatol · 2025-07-30

本研究整合甲基化结合域测序、RNA测序、450K芯片及TCGA数据,筛选黑色素瘤预后DNA甲基化标志物,并在两个独立队列及TCGA数据中验证。LY75启动子甲基化、Breslow厚度和诊断时转移性疾病是無復發生存的显著独立预测因子,LY75甲基化亦独立预测局限期I/II期患者转移发生。

要点

  • LY75启动子甲基化是黑色素瘤无复发生存的独立预测因子。
  • LY75甲基化独立预测局限期I/II期黑色素瘤的转移发生。
  • 该标志物有助于细化前哨淋巴结活检、影像学和辅助治疗的患者选择。

核心结论

  • LY75启动子甲基化独立于常规预后参数,可识别复发或转移高风险的黑色素瘤患者。

研究设计与样本

  • 整合甲基结合域测序、RNA测序、Infinium HumanMethylation450分析及TCGA数据筛选候选标志物。
  • 采用甲基化特异性PCR在两个独立黑色素瘤队列中验证,并用TCGA数据进行计算机验证。
  • 使用Cox比例风险模型和向后逐步消除法确定候选标志物的预后价值。

主要发现

  • LY75启动子甲基化、Breslow厚度和诊断时转移性疾病是无复发生存的显著独立预测因子。
  • LY75启动子甲基化是局限期I/II期黑色素瘤患者发生转移性疾病的独立预测因子。
  • 该关联在第二验证队列和TCGA黑色素瘤数据集中得到确认。

关键数值与推荐

  • LY75启动子甲基化、Breslow厚度和诊断时转移性疾病为无复发生存的独立预测因子。
  • LY75启动子甲基化独立预测局限期I/II期黑色素瘤的转移发生。

临床怎么用

  • LY75启动子甲基化可辅助识别复发或转移高风险患者,独立于常规预后参数。
  • 该标志物可能帮助细化前哨淋巴结活检、影像学检查、(新)辅助治疗和密切监测的患者选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accurate risk assessment of local recurrences or metastases is essential for melanoma treatment, but current clinical parameters are suboptimal. Therefore, we conducted a comprehensive DNA methylation analysis to identify prognostic markers that could improve risk prediction in patients with melanoma. We integrated methyl-binding domain sequencing, RNA sequencing, Infinium HumanMethylation450 analyses, and The Cancer Genome Atlas data to identify potential prognostic DNA methylation markers. Validation was performed using methylation-specific PCR in 2 independent melanoma cohorts as well as an in silico validation using The Cancer Genome Atlas data. Cox proportional hazards models and backward stepwise elimination determined the prognostic value of candidate markers. LY75 promoter methylation, Breslow thickness, and metastatic disease at diagnosis were significant independent predictors of recurrence-free survival. LY75 promoter methylation was also found to be an independent predictor of metastatic disease development in patients with localized stage I/II melanoma specifically. This association was confirmed in a second validation cohort and The Cancer Genome Atlas melanoma dataset. LY75 promoter methylation identifies patients at high risk of recurrences or metastases, independent of conventional prognostic parameters. This marker could help refine patient selection for sentinel node biopsies, imaging, (neo)adjuvant treatment, and closer monitoring, ultimately leading to improved clinical outcomes.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. van den Hurk K, Lommen K, Coussement L, et al. Comprehensive Analysis of the Melanoma DNA Methylome Identifies LY75 Methylation as an Independent Marker Predicting Poor Clinical Outcome. J Invest Dermatol. 2025. PMID: 40749971. doi:10.1016/j.jid.2025.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。